Riluzole

Evidence Level: L5

Predicted Indications: 8

Riluzole

Pharmacist Assessment Report

Riluzole: From Amyotrophic Lateral Sclerosis to Bilateral Parasagittal Parieto-occipital Polymicrogyria

One-Sentence Summary

Riluzole is a drug originally used to treat amyotrophic lateral sclerosis (ALS). The TxGNN model predicts it may be effective for bilateral parasagittal parieto-occipital polymicrogyria (a rare cortical malformation), but no clinical trials and no publications currently support this specific prediction. It rests on the model score alone.

Quick Overview

Item	Content
Original Indication	Amyotrophic lateral sclerosis
Predicted New Indication	Bilateral parasagittal parieto-occipital polymicrogyria
TxGNN Prediction Score	0.9999
Evidence Level	L5
Canada Market Status	Marketed (marketed DINs: 3 of 3)
Number of DINs	3 (marketed: 3)
Recommended Decision	Hold

Why is This Prediction Reasonable?

Detailed mechanism of action data is not available in the data compiled for this report. Based on general knowledge, riluzole modulates glutamate signaling and voltage-gated sodium channels. This is the basis of its use in ALS, where excitotoxicity in motor neurons is thought to play a role.

The link to polymicrogyria is speculative. Cortical malformations are often associated with epilepsy and abnormal neuronal excitability, so a modulator of glutamate and sodium channels could theoretically be relevant. No data supplied here support this link, and the very high score (0.9999) should be read as a model output only, not as evidence of efficacy.

Other top-ranked predictions were also reviewed. Several are motor neuron conditions that overlap biologically with ALS (lower motor neuron syndrome, monomelic amyotrophy, Mills syndrome, ALS type 22). These are mechanistically more plausible than the top-ranked prediction, but they also have no disease-specific trial data. Others, such as axial spondylometaphyseal dysplasia, have no evident mechanistic link. Their scores come from the TxGNN model (deep learning) and may reflect similarities the model learned between related diseases, not biological evidence.

Clinical Trial Evidence

Currently no related clinical trials registered.

Literature Evidence

Currently no related literature available for the top-ranked predicted indication.

Canada Market Information

DIN	Product Name	Dosage Form	Approved Indication
02352583	APO-RILUZOLE	Not specified	Not specified
02390299	MYLAN-RILUZOLE	Not specified	Not specified
02242763	RILUTEK	Not specified	Not specified

All three authorizations are valid single-ingredient products.

Safety Considerations

Knowledge-graph contraindication associations (these come from a knowledge graph, not from package insert text):

Neutropenia and agranulocytosis
Substance abuse/dependence
Hyperbilirubinemia, hereditary hyperbilirubinemia, and Gilbert syndrome
Interstitial lung disease
Drug-induced liver injury

Drug Interactions: 44 interactions were identified. Examples from the first 20 listed:

Moderate: obeticholic acid, naltrexone, deferasirox, osilodrostat, anagrelide, asparaginase Escherichia coli, brentuximab vedotin, clofarabine, methotrexate, epirubicin
Minor: omeprazole, caffeine, theophylline, aminophylline
Severity unknown: metformin, simvastatin, ranitidine, cyanocobalamin, salbutamol, ibuprofen

Please refer to the package insert for warnings and contraindications from the approved label.

Conclusion and Next Steps

Decision: Hold

Rationale: The prediction rests on a model score only, with no clinical trials or literature for polymicrogyria. The mechanistic link is speculative. The Canada label information (warnings, contraindications, approved indication text) is also incomplete.

To proceed, the following is needed:

Mechanism of action data for riluzole
Health Canada package insert warnings, contraindications, and approved indication text
Preclinical or clinical evidence in cortical malformation or malformation-associated epilepsy
Given the knowledge-graph liver and haematological contraindication associations, a monitoring plan for liver function and blood counts
Consideration of the motor neuron predictions (e.g., lower motor neuron syndrome, ALS type 22) as more plausible alternatives, each needing disease-specific evidence
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.